Erik Castle, MD

Erik Castle, MD

Mayo Clinic

Phoenix, AZ

Dr. Erik Castle received his MD from University of Texas, Southwestern Medical Center at Dallas in 1998. Dr. Castle is a Professor of Urology at the Mayo Clinic in Arizona and has been practicing for 16 years. He practices medicine in Scottsdale AZ and two other locations and specializes in Surgical Urology. Dr. Castle is also the director of the Desert Mountain Care Prostate Cancer Research Fund. Dr. Castle has been the Director of the International Laparoscopic Nephrectomy courses throughout Mexico on behalf of the American Urological Association (AUA) since 2008 and has been a voting member of the Laparoscopic, Robotic and New Surgical Technology Committee since 2010. Also with the AUA, Dr. Castle was a member of the Microscopic Hematuria Guidelines Committee from 2010-2012 and was the President of the Society of Urologic Robotic Surgeons from 2009-2010. Now he is the Associate Editor with the Journal of Robotic Surgery and has been since 2010. Dr. Castle’s research interests include prostate cancer, bladder cancer, and kidney cancer. In basic science research, he focuses on novel secondary hormonal therapies for prostate cancer and apoptotic pathways related to manipulations of the androgen and estrogen receptors. He also performs research into the genomics of prostate and bladder cancer. Dr. Castle directs the outcomes research of robotic and laparoscopic surgery for these three cancers and he is the principal investigator in the ongoing urologic oncology biorepository in his laboratory.

Articles by Erik Castle, MD

HIFU is not Ready for Prime Time

Erik P. Castle, MD, argues that using high intensity focused ultrasound (HIFU) to treat prostate cancer, as the technology stands today, results in too many negative quality of life outcomes for patients. Therefore, HIFU is not ready to be a standard of care in urological practices.

Read More

BCG Maintenance – Full SWOG Course – Pro Argument

Erik P. Castle, MD, explains the Southwest Oncology Group’s (SWOG’s) protocol for administering maintenance doses of bacillus Calmette-Guerin (BCG) to non-muscle invasive bladder cancer patients. He argues that carrying out the full SWOG course makes a positive impact on patients’ recurrence free survival rates, identifying the ideal disease types and patients to receive the full course.

Read More

Join the GRU Community

- Why Join? -